Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform
(Adnkronos) – NEW YORK and LONDON, June 12, 2023 /PRNewswire/ — Huma Therapeutics (“Huma”), a leading global digital health company, today announced that it has received U.S. Food and Drug Administration (FDA) Class
